烯醇化酶-α和C-MYC启动子结合蛋白-1基于PI3K/Akt通路调控肝细胞癌发生发展的研究进展

摘要
图/表
参考文献(32)
相关文章 (15)

全文: PDF (635 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要烯醇化酶-α（ENO1）是一种具有组织特异性表达的糖酵解关键酶，其参与糖酵解并影响此进程，C-MYC启动子结合蛋白-1（MBP-1）可抑制癌基因C-MYC的表达。目前发现，两者由同一基因编码表达，并且其表达调控与PI3K/Akt通路有着复杂的关系。ENO1和MBP-1可通过调控PI3K/Akt通路，在肝细胞癌（HCC）等肿瘤的进展和抑制中发挥重要作用。本文就ENO1和MBP-1的功能、表达调控、与PI3K/Akt通路的关系及基于该通路对HCC等癌症的作用机制进行简要综述，从而为HCC发生和进展的可能分子机制和可用于调控该机制的分子靶点提供一定的理论依据，并且为未来对于HCC的有效治疗提供新思路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	徐伟鑫王春芳罗艳红

关键词 ：烯醇化酶-&alpha, C-MYC启动子结合蛋白-1, PI3K/Akt通路, 肝细胞癌

Abstract：Enolase-α (ENO1) is a type of key glycolysis enzyme with tissue-specific expression, which participates in glycolysis and affects the process of glycolysis. C-MYC promoter binding protein-1 (MBP-1) can inhibit the expression of oncogene C-MYC. At present, it has been found that they are expressed by the same genetic encode, and there is a complex relationship between their expression regulation and the PI3K/Akt pathway. ENO1 and MBP-1 play an important role in the progression and inhibition of tumors such as hepatocellular carcinoma (HCC) by regulating the PI3K/Akt pathway. This paper briefly reviewes the function of ENO1 and MBP-1, their expression regulation, and their relationship with PI3K/Akt signal pathway as well as the mechanism of this pathway on HCC. Thus we can explore possible molecular mechanism for the occurrence and progression of HCC so as to provide a theoretical basis for molecular targets to regulate this mechanism. It aims to provide new ideas for the effective treatment of HCC in the future.

Key words： Enolase-α C-MYC promoter binding protein-1 PI3K/Akt pathway Hepatocellular carcinoma

基金资助:国家自然科学基金资助项目（81960303）；
右江民族医学院校级科研课题（yy2021sk012）。

通讯作者: 罗艳红（1965-），女，硕士，教授，硕士生导师；研究方向：中草药抗肝癌。

作者简介: 徐伟鑫（1982-），男，右江民族医学院基础医学院2020级免疫学专业在读硕士研究生；研究方向：肝癌机制。

引用本文:

徐伟鑫王春芳罗艳红. 烯醇化酶-α和C-MYC启动子结合蛋白-1基于PI3K/Akt通路调控肝细胞癌发生发展的研究进展[J]. 中国医药导报, 2022, 19(19): 53-56.
XU Weixin WANG Chunfang LUO Yanhong. Research progress of enolase -α and C-MYC promoter binding protein-1 regulating the occurrence and progression of hepatocellular carcinoma based on PI3K/Akt pathway. 中国医药导报, 2022, 19(19): 53-56.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I19/53

[1] Ji H，Wang J，Guo J，et al. Progress in the biological function of alpha-enolase [J]. Anim Nutr，2016，2（1）：12-17.
[2] Subramanian A，Miller DM. Structural analysis of α-enolase：mapping the functional domains involved in down-regulation of the c-myc protooncogene [J]. J Biol Chem，2000，275（8）：5958-5965.
[3] Trojanowicz B，Hoang-Vu C，Sekulla C. ENO1（Enolase 1，（alpha））[J]. Atlas Genet Cytogenet Oncol Haematol，2010，14（7）：635-640.
[4] Osthus RC，Shim H，Kim S，et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc [J]. J Biol Chem，2000，275（29）：21797-21800.
[5] Shi M，Dai WQ，Jia RR，et al. APCCDC20-mediated degradation of PHD3 stabilizes HIF-1a and promotes tumorigenesis in hepatocellular carcinoma [J]. Cancer Lett，2021， 496：144-155.
[6] Zhu X，Yu H，Li B，et al. Targetting an LncRNA P5848-ENO1 axis inhibits tumor growth in hepatocellular carcinoma [J]. Biosci Rep，2019，39（11）：1-8.
[7] Li L，Wang F，Zhang J，et al. Typical phthalic acid esters induce apoptosis by regulating the PI3K/Akt/Bcl-2 signaling pathway in rat insulinoma cells [J]. Ecotoxicol Environ Saf，2021，208：111461.
[8] D?觟rng P，Calvis DF，Dombrowski F. Nuclear ErbB2 expression in hepatocytes in liver disease [J]. Virchows Arch，2021，478（2）：309-318.
[9] Qiao G，Wu A，Chen X，et al. Enolase 1，a Moonlighting Protein，as a Potential Target for Cancer Treatment [J]. Int J Biol Sci，2021，17（14）：3981.
[10] Yang X，Sun J，Sun H，et al. MicroRNA-30a-3p acts as a tumor suppressor in MHCC-97H hepatocellular carcinoma cells by targeting COX-2 [J]. J Cancer，2021，12（13）：3945.
[11] Cheng R，Wang B，Cai X，et al. CD276 promotes vasculogenic mimicry formation in hepatocellular carcinoma via the PI3K/AKT/MMPs pathway [J]. Onco Targets Ther，2020，13：11485.
[12] Wang J，Han Y，Wang M，et al. Natural triterpenoid saponin Momordin Ic suppresses HepG2 cell invasion via COX-2 inhibition and PPARγ activation [J]. Toxicol In Vitro，2020，65：104784.
[13] Guo C，Gao C，Lv X，et al. CRKL promotes hepatocarcinoma through enhancing glucose metabolism of cancer cells via activating PI3K/Akt [J]. J Cell Mol Med，2021， 25（5）：2714-2724.
[14] Teng C，Hsieh W，Wu H，et al. Hepatitis B virus pre-S2 mutant induces aerobic glycolysis through mammalian target of rapamycin signal cascade [J]. PLoS One，2015， 10（4）：e122373.
[15] Mirabilii S，Ricciardi MR，Tafuri A. mTOR Regulation of Metabolism in Hematologic Malignancies [J]. Cells，2020， 9（2）：404.
[16] Sun L，Lu T，Tian K，et al. Alpha-enolase promotes gastric cancer cell proliferation and metastasis via regulating AKT signaling pathway [J]. Eur J Pharmacol，2019， 845：8-15.
[17] Dimri M，Humphries A，Laknaur A，et al. Nqo1 ablation inhibits activation of the PI3K/Akt and MAPK/ERK pathways and blocks metabolic adaptation in hepatocellular carcinoma [J]. Hepatology，2020，71（2）：549.
[18] Ni F，Huang X，Chen Z，et al. Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin [J]. Sci Rep，2018，8（1）：1-10.
[19] Ahn H，Im E，Lee D Y，et al. Antitumor effect of pyrogallol via miR-134 mediated S phase arrest and inhibition of PI3K/AKT/Skp2/cMyc signaling in hepatocellular carcinoma [J]. Int J Mol Sci，2019，20（16）：3985.
[20] Zhang M，Liu S，Chua M，et al. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway [J]. Cell Death Dis，2019，10（8）：1-15.
[21] Zheng H，Yang Y，Hong YG，et al. Tropomodulin 3 modulates EGFR-PI3K-AKT signaling to drive hepatocellular carcinoma metastasis [J]. Mol Carcinog，2019，58（10）：1897-1907.
[22] Tan W，Zhu S，Cao J，et al. Inhibition of MMP-2 expression enhances the antitumor effect of sorafenib in hepatocellular carcinoma by suppressing the PI3K/AKT/mTOR pathway [J]. Oncol Res，2017，25（9）：1543-1553.
[23] Ren F，Wu K，Yang Y，et al. Dandelion Polysaccharide Exerts Anti-Angiogenesis Effect on Hepatocellular Carcinoma by Regulating VEGF/HIF-1α Expression [J]. Front Pharmacol，2020，11：460.
[24] Wang L，Liu W，Huang X. MicroRNA-199a-3p inhibits angiogenesis by targeting the VEGF/PI3K/AKT signalling pathway in an in vitro model of diabetic retinopathy [J]. Exp Mol Pathol，2020，116：104488.
[25] Feng J，Li J，Wu L，et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma [J]. J Exp Clin Cancer Res，2020，39（1）：1-19.
[26] Panasyuk G，Espeillac C，Chvin C，et al. PPARγ contributes to PKM2 and HK2 expression in fatty liver [J]. Nat Commun，2012，3（1）：1-9.
[27] Chen J，Chen J，Huang J，et al. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway [J]. Aging（Albany NY），2019，11（23）：10839.
[28] Maranto C，Perconti G，Contino F，et al. Cellular stress induces cap-independent alpha-enolase/MBP-1 translation [J]. FEBS Lett，2015，589（16）：2110-2116.
[29] Czogalla B，Partenheimer A，Badmann S，et al. Nuclear Enolase-1/MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer [J]. Transl Oncol，2021，14（1）：100910.
[30] Varone E，Decio A，Chernorudskiy A，et al. The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions [J]. Oncogene，2021，40（9）：1721-1736.
[31] Novais EJ，Choi H，Madhu V，et al. Hypoxia and Hypoxia-Inducible Factor-1α Regulate Endoplasmic Reticulum Stress in Nucleus Pulposus Cells：Implications of Endoplasmic Reticulum Stress for Extracellular Matrix Secretion [J]. Am J Pathol，2021，191（3）：487-502.
[32] Liu Y，Liao L，An C，et al. α-Enolase lies downstream of mTOR/HIF1α and promotes thyroid carcinoma progression by regulating CST1 [J]. Front Cell Dev Biol，2021， 9：670019.